Clinical Trials | June 02, 2026
STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial
While overall survival data remain immature, the results pointed to a favourable trend.
While overall survival data remain immature, the results pointed to a favourable trend.
The filing is backed by results from the pivotal SERENA-6 Phase III trial
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
